AEON Biopharma, Inc. (AEON) Expects Cash to Fund Operations Into Q2 2027
AEON reported $11.4M in cash and cash equivalents at September 30, 2026, plus approximately $6.2M in Q4 warrant proceeds; together, these are expected to fund operations into Q2 2027. It submitted an IND for a comparative CMAP study, planned to begin in Q1 2027.Material DetailsContext by AI Analyst…